Orion's Molecular Diagnostics unit is developing a new class of Second Code diagnostic products to help physicians discover cancer during its earliest stage and confirm the diagnosis of cancer before beginning treatment.

Unlike other diagnostics companies whose methods focus on the "First Code", Orion Genomics has developed diagnostic products to take advantage of new research that shows errors in DNA's Second Code are far more prevalent, occur more frequently with age, and are linked to the presence of cancer. Our methylation-based molecular diagnostic kits are designed to indicate changes in DNA's Second Code that provide important information about the presence of cancer, its progression, and appropriate treatment options. We are currently developing diagnostic kits that can detect widespread cancer including breast, prostate, lung and colorectal. Future development of our products could benefit patients with many other types of cancer.